Does the media prefer MANE or JAZZ?

In the previous week, Jazz Pharmaceuticals had 15 more articles in the media than Veradermics. MarketBeat recorded 18 mentions for Jazz Pharmaceuticals and 3 mentions for Veradermics. Veradermics' average media sentiment score of 0.66 beat Jazz Pharmaceuticals' score of 0.51 indicating that Veradermics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradermics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jazz Pharmaceuticals 6 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NBIX or MANE?

In the previous week, Neurocrine Biosciences had 17 more articles in the media than Veradermics. MarketBeat recorded 20 mentions for Neurocrine Biosciences and 3 mentions for Veradermics. Veradermics' average media sentiment score of 0.66 beat Neurocrine Biosciences' score of 0.62 indicating that Veradermics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 8 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive Veradermics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ELAN or MANE?

In the previous week, Elanco Animal Health had 21 more articles in the media than Veradermics. MarketBeat recorded 24 mentions for Elanco Animal Health and 3 mentions for Veradermics. Elanco Animal Health's average media sentiment score of 0.85 beat Veradermics' score of 0.66 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 9 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Veradermics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CORT or MANE?

In the previous week, Corcept Therapeutics had 7 more articles in the media than Veradermics. MarketBeat recorded 10 mentions for Corcept Therapeutics and 3 mentions for Veradermics. Corcept Therapeutics' average media sentiment score of 1.11 beat Veradermics' score of 0.66 indicating that Corcept Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veradermics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AXSM or MANE?

In the previous week, Axsome Therapeutics had 27 more articles in the media than Veradermics. MarketBeat recorded 30 mentions for Axsome Therapeutics and 3 mentions for Veradermics. Veradermics' average media sentiment score of 0.66 beat Axsome Therapeutics' score of 0.45 indicating that Veradermics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 11 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Veradermics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Veradermics (MANE) Competitors

$110.30 -0.70 (-0.63%)

As of 11:47 AM Eastern

Compare

MANE vs. JAZZ, NBIX, ELAN, CORT, and AXSM

Should you buy Veradermics stock or one of its competitors? Veradermics's main competitors and comparable companies include Jazz Pharmaceuticals (JAZZ), Neurocrine Biosciences (NBIX), Elanco Animal Health (ELAN), Corcept Therapeutics (CORT), and Axsome Therapeutics (AXSM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Veradermics compare to Jazz Pharmaceuticals?

Veradermics (NYSE:MANE) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

In the previous week, Jazz Pharmaceuticals had 15 more articles in the media than Veradermics. MarketBeat recorded 18 mentions for Jazz Pharmaceuticals and 3 mentions for Veradermics. Veradermics' average media sentiment score of 0.66 beat Jazz Pharmaceuticals' score of 0.51 indicating that Veradermics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradermics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	6 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Veradermics currently has a consensus target price of $153.00, indicating a potential upside of 37.72%. Jazz Pharmaceuticals has a consensus target price of $272.89, indicating a potential upside of 12.02%. Given Veradermics' higher probable upside, analysts plainly believe Veradermics is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Jazz Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.95

Veradermics has higher earnings, but lower revenue than Jazz Pharmaceuticals. Veradermics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	-$70M	-$1.32	N/A
Jazz Pharmaceuticals	$4.27B	3.71	-$356.15M	$14.50	16.80

Jazz Pharmaceuticals has a net margin of 20.45% compared to Veradermics' net margin of 0.00%. Jazz Pharmaceuticals' return on equity of 33.97% beat Veradermics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Jazz Pharmaceuticals	20.45%	33.97%	13.02%

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 4.1% of Jazz Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Jazz Pharmaceuticals beats Veradermics on 12 of the 15 factors compared between the two stocks.

How does Veradermics compare to Neurocrine Biosciences?

Neurocrine Biosciences (NASDAQ:NBIX) and Veradermics (NYSE:MANE) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

Neurocrine Biosciences has higher revenue and earnings than Veradermics. Veradermics is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$2.86B	5.38	$478.60M	$6.82	22.18
Veradermics	N/A	N/A	-$70M	-$1.32	N/A

Neurocrine Biosciences has a net margin of 20.91% compared to Veradermics' net margin of 0.00%. Neurocrine Biosciences' return on equity of 22.43% beat Veradermics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	20.91%	22.43%	15.64%
Veradermics	N/A	N/A	N/A

Neurocrine Biosciences currently has a consensus price target of $200.86, indicating a potential upside of 32.79%. Veradermics has a consensus price target of $153.00, indicating a potential upside of 37.72%. Given Veradermics' higher possible upside, analysts plainly believe Veradermics is more favorable than Neurocrine Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.88
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

92.6% of Neurocrine Biosciences shares are owned by institutional investors. 4.6% of Neurocrine Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Neurocrine Biosciences had 17 more articles in the media than Veradermics. MarketBeat recorded 20 mentions for Neurocrine Biosciences and 3 mentions for Veradermics. Veradermics' average media sentiment score of 0.66 beat Neurocrine Biosciences' score of 0.62 indicating that Veradermics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	8 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradermics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Neurocrine Biosciences beats Veradermics on 13 of the 15 factors compared between the two stocks.

How does Veradermics compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Veradermics (NYSE:MANE) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

Veradermics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -3.96%. Elanco Animal Health's return on equity of 8.13% beat Veradermics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-3.96%	8.13%	3.99%
Veradermics	N/A	N/A	N/A

Elanco Animal Health currently has a consensus target price of $29.09, indicating a potential upside of 25.47%. Veradermics has a consensus target price of $153.00, indicating a potential upside of 37.72%. Given Veradermics' higher possible upside, analysts plainly believe Veradermics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Veradermics has lower revenue, but higher earnings than Elanco Animal Health. Veradermics is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.46	-$232M	-$0.41	N/A
Veradermics	N/A	N/A	-$70M	-$1.32	N/A

97.5% of Elanco Animal Health shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Elanco Animal Health had 21 more articles in the media than Veradermics. MarketBeat recorded 24 mentions for Elanco Animal Health and 3 mentions for Veradermics. Elanco Animal Health's average media sentiment score of 0.85 beat Veradermics' score of 0.66 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	9 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradermics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Elanco Animal Health beats Veradermics on 12 of the 15 factors compared between the two stocks.

How does Veradermics compare to Corcept Therapeutics?

Corcept Therapeutics (NASDAQ:CORT) and Veradermics (NYSE:MANE) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

Corcept Therapeutics has higher revenue and earnings than Veradermics. Veradermics is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$830.81M	14.53	$99.65M	$0.42	265.98
Veradermics	N/A	N/A	-$70M	-$1.32	N/A

In the previous week, Corcept Therapeutics had 7 more articles in the media than Veradermics. MarketBeat recorded 10 mentions for Corcept Therapeutics and 3 mentions for Veradermics. Corcept Therapeutics' average media sentiment score of 1.11 beat Veradermics' score of 0.66 indicating that Corcept Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradermics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Corcept Therapeutics has a net margin of 6.52% compared to Veradermics' net margin of 0.00%. Corcept Therapeutics' return on equity of 8.26% beat Veradermics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.52%	8.26%	6.45%
Veradermics	N/A	N/A	N/A

93.6% of Corcept Therapeutics shares are owned by institutional investors. 20.7% of Corcept Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Corcept Therapeutics currently has a consensus price target of $119.17, indicating a potential upside of 6.68%. Veradermics has a consensus price target of $153.00, indicating a potential upside of 37.72%. Given Veradermics' stronger consensus rating and higher probable upside, analysts plainly believe Veradermics is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Corcept Therapeutics beats Veradermics on 12 of the 15 factors compared between the two stocks.

How does Veradermics compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Veradermics (NYSE:MANE) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Veradermics has lower revenue, but higher earnings than Axsome Therapeutics. Veradermics is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	17.56	-$183.17M	-$3.75	N/A
Veradermics	N/A	N/A	-$70M	-$1.32	N/A

In the previous week, Axsome Therapeutics had 27 more articles in the media than Veradermics. MarketBeat recorded 30 mentions for Axsome Therapeutics and 3 mentions for Veradermics. Veradermics' average media sentiment score of 0.66 beat Axsome Therapeutics' score of 0.45 indicating that Veradermics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	11 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Veradermics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

81.5% of Axsome Therapeutics shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Veradermics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -24.68%. Veradermics' return on equity of 0.00% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-275.76%	-28.82%
Veradermics	N/A	N/A	N/A

Axsome Therapeutics currently has a consensus price target of $267.60, indicating a potential upside of 24.99%. Veradermics has a consensus price target of $153.00, indicating a potential upside of 37.72%. Given Veradermics' higher possible upside, analysts plainly believe Veradermics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	2 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.82
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Axsome Therapeutics beats Veradermics on 8 of the 15 factors compared between the two stocks.

Get Veradermics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MANE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MANE vs. The Competition

Export

Metric	Veradermics	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$4.63B	$11.70B	$6.97B	$24.27B
Dividend Yield	N/A	2.70%	2.58%	3.69%
P/E Ratio	-84.02	783.85	269.56	30.24
Price / Sales	N/A	747.98	596.64	20.62
Price / Cash	N/A	67.45	70.53	33.80
Price / Book	N/A	10.66	13.00	6.62
Net Income	-$70M	$2.77B	$3.45B	$1.06B
7 Day Performance	-2.08%	-0.25%	0.57%	0.58%
1 Month Performance	1.14%	-0.10%	1.22%	3.19%
1 Year Performance	N/A	160.98%	66.67%	18.73%

Veradermics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MANE Veradermics	2.3447 of 5 stars	$110.30 -0.6%	$153.00 +38.7%	N/A	$4.61B	N/A	N/A	19	Earnings Report
JAZZ Jazz Pharmaceuticals	4.0511 of 5 stars	$259.15 -0.9%	$272.74 +5.2%	+109.9%	$16.82B	$4.27B	17.87	2,890	Analyst Forecast
NBIX Neurocrine Biosciences	4.9864 of 5 stars	$162.00 +0.3%	$201.50 +24.4%	+14.6%	$16.48B	$2.86B	23.77	2,000	Analyst Downgrade
ELAN Elanco Animal Health	4.3645 of 5 stars	$24.08 -8.2%	$28.82 +19.7%	+26.3%	$12.02B	$5.02B	N/A	9,400	Insider Trade Gap Down
CORT Corcept Therapeutics	3.3707 of 5 stars	$107.74 -2.7%	$119.17 +10.6%	+51.8%	$11.65B	$761.41M	256.64	300	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:MANE) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veradermics (MANE) Competitors

MANE vs. JAZZ, NBIX, ELAN, CORT, and AXSM

How does Veradermics compare to Jazz Pharmaceuticals?

Summary

How does Veradermics compare to Neurocrine Biosciences?

Summary

How does Veradermics compare to Elanco Animal Health?

Summary

How does Veradermics compare to Corcept Therapeutics?

Summary

How does Veradermics compare to Axsome Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MANE vs. The Competition

Veradermics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Veradermics (MANE) Competitors

MANE vs. JAZZ, NBIX, ELAN, CORT, and AXSM

How does Veradermics compare to Jazz Pharmaceuticals?

Does the media prefer MANE or JAZZ?

Do analysts rate MANE or JAZZ?

Which has higher earnings and valuation, MANE or JAZZ?

Is MANE or JAZZ more profitable?

Do institutionals and insiders believe in MANE or JAZZ?

Summary

How does Veradermics compare to Neurocrine Biosciences?

Which has better earnings and valuation, NBIX or MANE?

Is NBIX or MANE more profitable?

Do analysts rate NBIX or MANE?

Do institutionals & insiders hold more shares of NBIX or MANE?

Does the media refer more to NBIX or MANE?

Summary

How does Veradermics compare to Elanco Animal Health?

Is ELAN or MANE more profitable?

Do analysts recommend ELAN or MANE?

Which has better valuation & earnings, ELAN or MANE?

Do insiders & institutionals hold more shares of ELAN or MANE?

Does the media favor ELAN or MANE?

Summary

How does Veradermics compare to Corcept Therapeutics?

Which has preferable earnings & valuation, CORT or MANE?

Does the media favor CORT or MANE?

Is CORT or MANE more profitable?

Do insiders and institutionals believe in CORT or MANE?

Do analysts rate CORT or MANE?

Summary

How does Veradermics compare to Axsome Therapeutics?

Which has preferable valuation and earnings, AXSM or MANE?

Does the media prefer AXSM or MANE?

Do insiders & institutionals hold more shares of AXSM or MANE?

Is AXSM or MANE more profitable?

Do analysts prefer AXSM or MANE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MANE vs. The Competition

Veradermics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools